Previous 10 | Next 10 |
2024-03-07 11:36:09 ET More on Emergent Biosolutions New CEO Appointment A Clear Positive For Emergent BioSolutions Emergent Biosolutions Q4 2023 Earnings Preview Emergent surges 66% as it brings in Bausch + Lomb vet Papa as CEO Read the full article on See...
2024-02-24 09:09:44 ET Summary Bausch Health is burdened by a heavy debt load of over $20 billion, impacting its equity valuation. The resolution to the leverage issues lies in divesting Bausch + Lomb Corp shares, which could bring in much-needed cash to reduce debt. The dives...
2024-02-21 13:11:49 ET More on Emergent Biosolutions Emergent BioSolutions: Q3 Numbers Leave Work To Be Done Emergent BioSolutions extends shelf life of Narcan to 4 years Emergent BioSolutions wins $235.8M DoD contract Seeking Alpha’s Quant Rating on E...
2024-02-21 13:07:09 ET Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Conference Call February 21, 2024, 8:00 a.m. ET Company Participants Brent Saunders - Chairman & CEO Sam Eldessouky - EVP & CFO George Gadkowski - VP, IR & Business Insights ...
2024-02-21 10:14:39 ET More on Bausch + Lomb Bausch + Lomb Corporation 2023 Q4 - Results - Earnings Call Presentation Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound Bausch + Lomb Q4 2023 Earnings Preview Eminence Capital adds Sea, AMD ...
2024-02-21 08:22:42 ET Gainers: Sound Group ( SOGP ) +113% Embraces Generative AI to Unveil New AI-Powered Applications. Origin Agritech ( SEED ) +57% reports FY results CN Energy Group ( CNEY ) +41% . Energy Focus ( EF...
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company’s debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address pu...
2024-02-21 06:59:25 ET More on Bausch + Lomb Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound Bausch + Lomb Q4 2023 Earnings Preview Eminence Capital adds Sea, AMD stakes; exits Peloton, Bausch + Lomb in Q4 Seeking Alpha’s Quant R...
Fourth-Quarter 2023 Financial Results Revenue of $1.173 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $54 Million Adjusted EBITDA (non-GAAP) 1 of $231 Million Revenue Grew 18% as Reported and 19% on a Constant Currency 1 Basis C...
Vimeo Inc. (VMEO) is expected to report $-0.01 for Q4 2023 Heineken N.V ADR (HEINY) is expected to report for Q4 2023 American States Water Company (AWR) is expected to report $0.53 for Q4 2023 NextPlay Technologies Inc. (NXTP) is expected to report for Q3 2024 Inseego Corp. (INSG...
News, Short Squeeze, Breakout and More Instantly...
Bausch + Lomb Corporation Company Name:
BLCO Stock Symbol:
NYSE Market:
Bausch + Lomb Corporation Website:
Events Include Symposium on Patient-Centric Approaches to Dry Eye, Highlighting Breakthroughs in Diagnosis, Treatment and Care Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the pre...
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily disposable contact lenses. Engineered with a next-generation lens material inf...
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink NutriTears, a clinically proven over-the-counter supplement that targets the key root causes of dry eyes, promotes health...